Jul 15, 2026 · 6 min
IBM shares plunge while SpaceX nears highly anticipated IPO valuation
IBM Historic Plunge; Financials Report; SpaceX Near IPO Price
The stark contrast between IBM's sudden market drop and SpaceX's rising private valuation reveals where investors are placing their long-term bets in technology and aerospace.
- 1IBM faces intense market scrutiny as its latest financial report triggers a historic stock plunge.
- 2SpaceX continues its upward trajectory in the private market as it nears its target IPO valuation.
- 3The contrasting market moves highlight a growing divergence between legacy tech earnings and high-growth sectors.
The brief
IBM shares experienced a historic plunge following its latest financial report, signaling deeper integration and execution challenges within the enterprise tech sector as legacy giants race to modernize.
At the same time, private market valuations continue to soar, highlighted by SpaceX approaching its highly anticipated initial public offering price amidst sustained investor demand.
These divergent market movements underscore a shifting landscape where traditional tech firms face intense scrutiny over earnings, while high-growth aerospace firms command premium valuations.
What was said on this episode
7 statements · 6 positive · 1 negative
Johnson & Johnson shares fell despite earnings beats and modestly raised 2026 guidance.
“Johnson and Johnson shares trading under ticker JNJ are down almost 2% in the premarket after the pharma company beat second quarter top and bottom line estimates and the company modestly raised its 2026 sales and profit guidance.”
Listen at 1:00
Johnson & Johnson’s earnings beat was driven by drug growth in several therapeutic areas.
“The company's beat was driven by growth for its of cancer, inflammatory diseases and treatment resistant depression drugs.”
Listen at 1:35
Johnson & Johnson’s results suggest drug makers are thriving despite regulatory and pricing pressures.
“This company is suggesting drug makers are thriving despite some recent turmoil at the FDA and some deals with the White House to lower net prices on some medicines.”
Listen at 1:55
BlackRock reported a strong earnings beat with $15.3 trillion under management.
“Very solid beat, $15.3 trillion in assets under management.”
Listen at 2:16
BlackRock’s inflows were primarily driven by ETFs and several investment strategies.
“The inflows were driven pretty broad, based primarily by ETFs, private market, active fixed income and systematic equity strategies and money.”
Listen at 2:36
BlackRock’s organic base fees grew 8%.
“The money manager saw an 8% growth in organic base fees”
Listen at 2:45
ASML machines manufacture chips that are in high demand.
“The company's machines, as I said, are used to make chips that are in high demand.”
Listen at 3:33
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Listen to the full episode and explore every guest, topic, and moment on PodLume.